Rigel Pharmaceuticals

Expansion And Clinical Pipeline Will Drive Future Opportunities Despite Risks

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

09 Feb 25

Updated

22 Nov 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

77.1%

7D

8.7%

Loading

1Y

77.1%

7D

8.7%

You can edit this narrative until Nov 23 2:10 AM. Then, changes will post as Updates.

Author's Valuation

US$46.60.8% undervalued

AnalystConsensusTarget Fair Value

Shared on 22 Nov 25

Fair value Increased 2.64%

RIGL: Future Results Will Reflect Continued Strong Commercial Execution Performance

Analysts have raised their price target for Rigel Pharmaceuticals from $45.40 to $46.60. They cite stronger-than-expected product sales, improved profit margins, and continued commercial execution as key factors behind the positive outlook.

Shared on 07 Nov 25

Fair value Increased 18%

RIGL: Strong Commercial Execution Will Drive Momentum As Upside Is Forecast

Analysts have raised their price target for Rigel Pharmaceuticals from approximately $38.33 to $45.40. They cite improved revenue growth, expanding profit margins, and stronger commercial execution following the company’s better-than-expected sales results and increased future guidance.

Shared on 07 Aug 25

Fair value Increased 14%

Despite a marked slowdown in consensus revenue growth forecasts, a significant improvement in net profit margin has driven the consensus analyst price target for Rigel Pharmaceuticals up from $33.74 to $36.83. What's in the News Raised 2025 total revenue guidance to $270–280 million (from $200–210 million), with net product sales of $210–220 million and collaboration contract revenues of $60 million (from $15–18 million).

Shared on 01 May 25

Fair value Decreased 7.23%

Shared on 23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 13%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 12 Mar 25

Fair value Decreased 4.81%

AnalystConsensusTarget has decreased revenue growth from 15.7% to 12.8%, decreased profit margin from 16.9% to 13.7% and increased future PE multiple from 15.4x to 20.8x.

AnalystConsensusTarget Fair Value

US$46.6

0.8% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

7.38%

Biotech revenue growth rate

8.57%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.12%

Calculation

US$109.11m

Earnings '28

x

9.97x

PE Ratio '28

=

US$1.09b

Market Cap '28

US$1.09b

Market Cap '28

/

19.04m

No. shares '28

=

US$57.14

Share Price '28

US$57.14 Share Price '28

Discounted to 2025 @ 7.12% p.a.

=

US$46.49

Fair Value '25